Patents by Inventor Frédéric Dhainaut
Frédéric Dhainaut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160009761Abstract: The invention relates to a method for purifying or detecting a target protein present in a solution, wherein said method comprises, before carrying out the purification or detection step itself, the step of contacting said solution with an aptamer binding specifically to said target protein, wherein said aptamer does not bind to any protein homologous to said target protein that could also be present in the solution.Type: ApplicationFiled: September 22, 2015Publication date: January 14, 2016Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Laurent Siret, Abdessatar Chtourou, Frederic Dhainaut, Gerald Perret
-
Patent number: 9175034Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.Type: GrantFiled: August 13, 2008Date of Patent: November 3, 2015Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Laurent Siret, Abdessatar Chtourou, Frédéric Dhainaut, Gérald Perret
-
Patent number: 8790881Abstract: A method for measuring immunoglobulin G-mediated complement activation, includes the following steps: a) preparing a sample A of immunoglobulin G and a sample B including natural serum, the natural serum optionally being diluted in a dilution buffer; b) mixing sample A with sample B at a ratio (amount of IgG in A in grams):(volume of natural serum in B in liters) of between and 75, at a temperature of between 2° C. and 6° C., and subsequently incubating the resulting reaction mixture at a temperature of between 35° C. and 40° C. for a period of between 30 minutes and 2 hours; c) cooling the reaction mixture obtained at the end of step b) to a temperature of between 0° C. and 4° C. in the presence of EDTA; and d) measuring the amount of C5a fragment in the cooled reaction mixture obtained in c).Type: GrantFiled: May 4, 2011Date of Patent: July 29, 2014Assignee: Laboratoire francais du Fractionnement et des BiotechnologiesInventors: Frederic Dhainaut, Gerald Perret
-
Publication number: 20130052659Abstract: A method for measuring immunoglobulin G-mediated complement activation, includes the following steps: a) preparing a sample A of immunoglobulin G and a sample B including natural serum, the natural serum optionally being diluted in a dilution buffer; b) mixing sample A with sample B at a ratio (amount of IgG in A in grams):(volume of natural serum in B in liters) of between and 75, at a temperature of between 2° C. and 6° C., and subsequently incubating the resulting reaction mixture at a temperature of between 35° C. and 40° C. for a period of between 30 minutes and 2 hours; c) cooling the reaction mixture obtained at the end of step b) to a temperature of between 0° C. and 4° C. in the presence of EDTA;and d) measuring the amount of C5a fragment in the cooled reaction mixture obtained in c).Type: ApplicationFiled: May 4, 2011Publication date: February 28, 2013Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Frederic Dhainaut, Gerald Perret
-
Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs
Patent number: 8153382Abstract: The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG.Type: GrantFiled: December 26, 2006Date of Patent: April 10, 2012Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies Societe AnonymeInventors: Abdessatar Chtourou, Frederic Dhainaut, Philippe Paolantonacci -
Publication number: 20100323368Abstract: The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.Type: ApplicationFiled: September 28, 2009Publication date: December 23, 2010Inventors: Christophe de Romeuf, Christine Gaucher, Arnaud Glacet, Frédéric Dhainaut, Dominique Bourel, Nicolas Bihoreau, Emmanuel Nony
-
Patent number: 7595165Abstract: The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.Type: GrantFiled: September 15, 2003Date of Patent: September 29, 2009Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Christophe de Romeuf, Christine Gaucher, Arnaud Clacet, Frédéric Dhainaut, Dominique Bourel, Nicolas Bihoreau, Emmanuel Nony
-
Publication number: 20090176220Abstract: The present invention relates to a method for measuring the ability of an antibody preparation to activate an Fc receptor, wherein this method comprises the following steps: a) aggregating said antibodies with one another, b) bringing cells expressing an Fc receptor into contact with said aggregated antibodies, and c) measuring the reaction of the cells resulting from the activation of the Fc receptor of said cells by the Fc region of said antibodies.Type: ApplicationFiled: December 15, 2006Publication date: July 9, 2009Applicant: LFB BiotechnologiesInventors: Frederic Dhainaut, Jean-Luc Teillaud, Laurent Siret
-
IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES AND OF POLYREACTIVE IgGs
Publication number: 20090074749Abstract: The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG.Type: ApplicationFiled: December 26, 2006Publication date: March 19, 2009Inventors: Abdessatar Chtourou, Frederic Dhainaut, Philippe Paolantonacci -
Publication number: 20050249732Abstract: The invention relates to a method of measuring the activation of an effector cell belonging to the immune which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.Type: ApplicationFiled: September 15, 2003Publication date: November 10, 2005Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Christophe de Romeuf, Christine Gaucher, Arnaud Glacet, Frederic Dhainaut, Dominique Bourel
-
Patent number: 6932969Abstract: The invention concerns a method for preparing Ig fractions from human polyvalent intravenous Immunoglobulins (IV Ig) which are in particular likely to be responsible for the immunomodulatory effect observed during the treatment of certain autoimmune diseases. The invention concerns Ig fractions having reactivity to IgM, IgG F(ab?)2 or DNP hapten and no or little reactivity to non-self antigens, that is Ig fractions which have idiotypic interactions among themselves (connected fraction) or which include natural antibodies reacting with the DNP hapten. Said fractions exhibit a polyreactivity to specific autoantigens.Type: GrantFiled: June 7, 2000Date of Patent: August 23, 2005Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Dominique Bourel, Martine Bruley-Rosset, Frédéric Dhainaut, Jacky Lirochon
-
Publication number: 20050089520Abstract: The invention concerns natural antibodies eventually monoclonal capable of inducing a high production of IL-1Ra with monocytes or macrophages and the use of said antibodies for treating inflammatory or autoimmune diseases.Type: ApplicationFiled: November 8, 2002Publication date: April 28, 2005Inventors: Dominique Bourel, Martine Bruley-Rosset, Frederic Dhainaut, Jacky Lirochon